



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	94245	CEFOTAXIME INJECTION cefotaxime 2g (as sodium) powder for injection vial
ARTG entry for	Medicine Registered	
Sponsor	Lupin Australia Pty Limited	
Postal Address	Suite 2 Level 2 19-23 Prospect Street, Box Hill, VIC, 3128 Australia	
ARTG Start Date	27/07/2004	
Product Category	Medicine	
Status	Active	
Approval Area	Drug Safety Evaluation Branch	

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . CEFOTAXIME INJECTION cefotaxime 2g (as sodium) powder for injection vial

Product Type	Single Medicine Product	Effective Date	5/02/2007 9:40:37 AM
---------------------	-------------------------	-----------------------	----------------------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Cefotaxime Injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. Infections of the respiratory tract (upper and lower). Infections of the urinary tract. Septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. Intra-abdominal infection. Gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of N. gonorrhoeae.) Ear, nose and throat (ENT) infections. Skin and skin structure infections. Bone and joint infections. Meningitis - Cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin G) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. In adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. Cefotaxime Injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. In serious cases, Cefotaxime Injection may be used, if considered appropriate, before the results of sensitivity tests become available. The emergence of resistance to cefotaxime may complicate treatment.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Medicine Component

Dosage Form	Injection, powder for
Route of Administration	Intravenous
Visual Identification	Clear glass vial containing a white to slightly yellow powder.

Active Ingredients

cefotaxime sodium	2097 mg
Equivalent: cefotaxime	2000 mg

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary